Literature DB >> 33822319

Non-functioning pituitary macroadenomas: factors affecting postoperative recurrence, and pre- and post-surgical endocrine and visual function.

Venkatram Subramanian1, Rachel Su Min Lee2, Simon Howell1, Samuel Gregson3, Ian M Lahart4, Kalpana Kaushal1,2, Joseph M Pappachan5,6,7.   

Abstract

BACKGROUND: Non-functioning pituitary macroadenomas (NFPAs) with visual field defects are ideally managed by transsphenoidal tumour resection to improve vision, and long-term postsurgical follow up is necessary to monitor for tumour recurrence. Regular updates from global data are necessary for developing optimal management strategies of these tumours.
METHODS: Pre- and postoperative visual and endocrine profile, imaging characteristics and details of surgical interventions among patients with NFPAs managed between 2008 and 2019 in a UK regional centre were assessed. The radiological and surgical outcomes including postoperative complications, recurrence risk and the factors influencing outcomes also were assessed.
RESULTS: 105 cases with mean (SD) age 60.1 (14.3) years and follow-up duration 60 (37) months were studied. 67 (64%) patients were male. Five-year recurrence-free survival rate was 71.5% (95% confidence interval [CI] 62.7% to 81.6%) with 33 (31%) tumour recurrences of whom 20 (60%) received radiotherapy and 9 (27%) underwent further surgery. Younger age, tumour volume, and bilateral cavernous sinus extension were the predictors of recurrence on univariate analysis, while younger age was the only factor on multivariate analysis (Hazard ratio 0.95; 95% CI: 0.92, 0.97). 72/78 patients (92%) with preoperative visual field defects improved after surgery, of whom 27 (35%) had full recovery. 20 (24%) patients had recovery of an abnormal hormone axis. 15 patients (16%) developed perioperative complications such as cerebrospinal fluid leak (12 cases), meningitis (2 cases), and bleeding (2 cases).
CONCLUSIONS: Five-year recurrence-free survival after transsphenoidal resection for NFPAs was 71.5% with older age at surgery conferring lower risk of recurrence. Visual recovery/ improvement occurred in 92% of cases with preoperative visual defects following surgery.

Entities:  

Keywords:  Non-functioning pituitary macroadenoma (NFPA); Recurrence-free survival; Transsphenoidal resection; Visual field defect

Year:  2021        PMID: 33822319     DOI: 10.1007/s12020-021-02713-1

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  30 in total

1.  The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study.

Authors:  Tomas Thor Agustsson; Tinna Baldvinsdottir; Jon G Jonasson; Elinborg Olafsdottir; Valgerdur Steinthorsdottir; Gunnar Sigurdsson; Arni V Thorsson; Paul V Carroll; Márta Korbonits; Rafn Benediktsson
Journal:  Eur J Endocrinol       Date:  2015-11       Impact factor: 6.664

Review 2.  Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Primary Management of Patients With Nonfunctioning Pituitary Adenomas.

Authors:  Joshua William Lucas; Mary E Bodach; Luis M Tumialan; Nelson M Oyesiku; Chirag G Patil; Zachary Litvack; Manish K Aghi; Gabriel Zada
Journal:  Neurosurgery       Date:  2016-10       Impact factor: 4.654

Review 3.  Pituitary-Tumor Endocrinopathies.

Authors:  Shlomo Melmed
Journal:  N Engl J Med       Date:  2020-03-05       Impact factor: 91.245

4.  Non-functioning pituitary macroadenoma: surgical outcomes, tumor regrowth, and alterations in pituitary function-3-year experience from the Iranian Pituitary Tumor Registry.

Authors:  Atousa Najmaldin; Mojtaba Malek; Nahid Hashemi Madani; Mohammad Ghorbani; Hamideh Akbari; Alireza Khajavi; Omolbanin Asadi Qadikolaei; Mohammad Ebrahim Khamseh
Journal:  Hormones (Athens)       Date:  2019-04-27       Impact factor: 2.885

5.  Descriptive epidemiology of pituitary tumors in the United States, 2004-2009.

Authors:  Haley Gittleman; Quinn T Ostrom; Paul D Farah; Annie Ondracek; Yanwen Chen; Yingli Wolinsky; Carol Kruchko; Justin Singer; Varun R Kshettry; Edward R Laws; Andrew E Sloan; Warren R Selman; Jill S Barnholtz-Sloan
Journal:  J Neurosurg       Date:  2014-06-13       Impact factor: 5.115

Review 6.  Management of clinically non-functioning pituitary adenoma.

Authors:  Philippe Chanson; Gerald Raverot; Frédéric Castinetti; Christine Cortet-Rudelli; Françoise Galland; Sylvie Salenave
Journal:  Ann Endocrinol (Paris)       Date:  2015-06-10       Impact factor: 2.478

7.  Demographic differences in incidence for pituitary adenoma.

Authors:  Bradley D McDowell; Robert B Wallace; Ryan M Carnahan; Elizabeth A Chrischilles; Charles F Lynch; Janet A Schlechte
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

8.  Results of transsphenoidal surgery in a large series of patients with pituitary adenoma.

Authors:  Pietro Mortini; Marco Losa; Raffaella Barzaghi; Nicola Boari; Massimo Giovanelli
Journal:  Neurosurgery       Date:  2005-06       Impact factor: 4.654

Review 9.  The prevalence of pituitary adenomas: a systematic review.

Authors:  Shereen Ezzat; Sylvia L Asa; William T Couldwell; Charles E Barr; William E Dodge; Mary Lee Vance; Ian E McCutcheon
Journal:  Cancer       Date:  2004-08-01       Impact factor: 6.860

Review 10.  Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas.

Authors:  O M Dekkers; A M Pereira; J A Romijn
Journal:  J Clin Endocrinol Metab       Date:  2008-08-05       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.